Single Cell Sequencing Analysis of Thymoma

The purpose of this study is to understand how genetics play a role in thymoma. Intratumoral heterogeneity is among the greatest challenges in precision cancer therapy. However, developments in high-throughput single-cell RNA sequencing (scRNA-seq) may now provide the statistical power to dissect the diverse cellular populations of tumors. This study aims to find out how it affects genetic and protein expression in patients with malignant thymoma, compared to Benign thymoma, at a single-cell level using a flow cytometry and RNA-sequencing protocol.

Study Overview

• Status: Recruiting
• Conditions: Thymoma
• Intervention / Treatment: Diagnostic test: Tissue

• Study Type: Observational
• Enrollment (Anticipated): 10

Contacts and Locations

• Study Contact: Name: An ZHAO, MD, PHD; Phone Number: 8688122413; Email: zhaoan@zjcc.org.cn

Study Locations

• China
  • Hangzhou, China, 310022
    • Recruiting
    • An Zhao
    • Contact: An Zhao, Dr; Phone Number: +8618258863556; Email: zhaoan@zjcc.org.cn
    • Principal Investigator: An Zhao, PHD
    • Principal Investigator: Zongping Wang, MD
    • Principal Investigator: Yipeng Xu, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients referred to the clinic for investigation of a suspected thymoma condition

Description

Inclusion Criteria:

• Patients diagnosed with thymoma
• Ability to provide written consent and comply with the protocol
• At least 18 years of age

Exclusion Criteria:

• Patients undergoing thymoma treatment
• Patients with previous malignancy
• Known HIV positive status.
• Evidence of abnormality of any immune cell population from a drug-induced or genetic cause.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Malignant thymoma	Diagnostic test: Tissue; Four 4-5 mm tissues of the thymoma
Benign thymoma	Diagnostic test: Tissue; Four 4-5 mm tissues of the thymoma

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determination of cell population from thymoma	The genes expression and the cell population	through study completion, an average of 1 year

Collaborators and Investigators

• Sponsor: Zhejiang Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Actual): June 6, 2020
• Primary Completion (Actual): June 1, 2021
• Study Completion (Anticipated): December 31, 2023

Study Registration Dates

• First Submitted: November 6, 2019
• First Submitted That Met QC Criteria: November 11, 2019
• First Posted (Actual): November 14, 2019

Study Record Updates

• Last Update Posted (Estimate): January 13, 2023
• Last Update Submitted That Met QC Criteria: January 12, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Lymphatic Diseases; Neoplasms by Site; Thoracic Neoplasms; Neoplasms, Complex and Mixed; Thymoma; Thymus Neoplasms
• Other Study ID Numbers: SCS-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: There is no plan to make individual participant data (IPD) available to other researchers

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No